<DOC>
	<DOC>NCT00484237</DOC>
	<brief_summary>This study will compare the safety and efficacy for two regimens of etanercept in patients with rheumatoid arthritis (RA). The two regimens to be compared are a 25mg twice weekly regimen and a 50mg once weekly regimen.</brief_summary>
	<brief_title>A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This study will compare the safety and efficacy for two regimens of etanercept in patients with rheumatoid arthritis (RA). The two regimens to be compared are a 25mg twice weekly regimen and a 50mg once weekly regimen.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Presence of &gt;6 swollen joints and &gt;6 tender joints Inadequate response to at least one disease modifying antirheumatic drug (DMARD) Have not been treated with a DMARD for at least 4 weeks prior to the baseline visit Previous treatment with etanercept, antibody to TNFα, or other TNFα inhibitors Received investigational drugs within 6 months of the baseline visit Received intraarticular hyaluronic acid injections within 4 weeks of the baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>